International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Premarin: The Intriguing History of a Controversial Drug

Author(s): Vance Dwight A

Issue: Jul/Aug 2007 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 282-286

Premarin: The Intriguing History of a Controversial Drug Page 1

Premarin: The Intriguing History of a Controversial Drug Page 2

Premarin: The Intriguing History of a Controversial Drug Page 3

Premarin: The Intriguing History of a Controversial Drug Page 4

Premarin: The Intriguing History of a Controversial Drug Page 5

Download in electronic PDF format for $75

Abstract: Premarin, a complex of conjugated equine estrogens manufactured by Wyeth for use as hormone replacement therapy in women, was originally developed by the Canadian pharmaceutical firm Ayerst, McKenna and Harrison. The name Premarin was coined from pregnant mare urine, from which the estrogen complex was isolated. Although the complete composition of Premarin and its active components remains undisclosed or unknown, Wyeth reports that it contains a mixture of 10 estrogens. The history of Premarin is entangled in a fascinating story of human intrigue involving ingenuity, influence, controversy, animal rights, competition, money, protection of stockholders, government regulatory power, patient rights, emotions, greed, power, personal and professional freedom, state rights, and perhaps even, ultimately, constitutional issues. As the saga of Premarin evolves, it no doubt will continue to be one of the more interesting and compelling stories of the practice of pharmacy.

Related Keywords: Dwight A. Vance, DPh, Premarin, pregnant mare urine, conjugated equine estrogens, progestin, Prempro, hormone replacement therapy, HRT, U.S. Food and Drug Administration, FDA, regulation, regulatory

Related Categories: BUSINESS, HISTORY, HRT, LEGAL, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Premarin: The Intriguing History of a Controversial Drug Vance Dwight A	Jul/Aug 2007 Pg. 282-286
The Science Behind Hormone Replacement Therapy, Part 1 Wepfer Scott T	Nov/Dec 2001 Pg. 462-464
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Deleruyelle Laura J	Sep/Oct 2016 Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 Deleruyelle Laura J	Nov/Dec 2016 Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3 Deleruyelle Laura J	Jan/Feb 2017 Pg. 6-16
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Bioidentical Hormone Replacement Therapy, Part 3, A Review of Wepfer Scott T	Mar/Apr 2002 Pg. 142-146
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
Hormone Replacement Therapy, Part 2: Estrogen Defined Lorentzen Jean	Nov/Dec 2001 Pg. 460-461
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Ford Gina, Garcia Lea	Jan/Feb 2001 Pg. 52-54
Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment Lorentzen Jean	Sep/Oct 2001 Pg. 336-338
Return to Top